Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HN2301 in Autoimmune Diseases
NCT06801119Phase 1Recruiting
- Sponsor
- Shenzhen MagicRNA Biotechnology
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HN-2301 in systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and rheumatoid arthritis (RA), sponsored by Shenzhen MagicRNA Biotechnology. Primary endpoint: Treatment-Emergent Adverse Events at 3 months. Started Mar 2025; status: recruiting.
02
Drugs
HN-2301
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06801119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06801119.